GSK, Zhifei to co-promote shingles vaccine Shingrix in China
Subject to the terms of the agreement, Zhifei will purchase agreed volumes of Shingrix with a value to GSK of £2.5 billion in total over the initial three-year period.
London: GSK plc has announced that it has reached an exclusive agreement with Chongqing Zhifei Biological Products, Ltd. to co-promote GSK’s shingles vaccine, Shingrix, in China for an initial three-year period, with the potential to extend the partnership should all parties agree.
By bringing together the scale and expertise of the two companies, the strategic partnership will significantly extend the availability of Shingrix, supporting the rapid expansion of patient access to the vaccine and future potential indications.
Set to start on 1 January 2024, Zhifei will have exclusive rights to import and distribute Shingrix in China – focusing on promoting the vaccine through its extensive service network, which covers more than 30,000 vaccination points across the country. In partnership, GSK - as the license holder for the product - will co-promote Shingrix by raising awareness of the importance of shingles vaccination amongst healthcare professionals within community health centres and hospital settings.
In August 2023, GSK announced positive data from the ZOSTER-076 phase IV trial showing that Shingrix demonstrated 100% vaccine efficacy in preventing shingles in Chinese adults aged 50 and over.
Luke Miels, Chief Commercial Officer, GSK said, “This partnership is consistent with our focus on products with a high and durable level of differentiation. It materially expands the number of Chinese adults who can benefit from Shingrix and includes the option to extend the collaboration to include our novel RSV vaccine Arexvy.”
Subject to the terms of the agreement, Zhifei will purchase agreed volumes of Shingrix with a value to GSK of £2.5 billion in total over the initial three-year period. These volumes are expected to be phased over this time as demand is expected to accelerate steadily through the period. There is potential to extend the partnership should all parties agree. The partnership supports and accelerates GSK’s commitment to double global Shingrix sales, reaching more than £4 billion by 2026.
Under the terms of the strategic partnership, Zhifei has granted GSK the right of first refusal to be their exclusive partner for any co-development and commercialisation of an RSV vaccine for older adults in China, paving the way for the companies to potentially partner on Arexvy upon approval in China.
Read also: British drugmaker GSK raises USD 1.1 billion from Haleon stake sale
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.